Literature DB >> 26342105

IL-18-induced interaction between IMP3 and HuR contributes to COX-2 mRNA stabilization in acute myeloid leukemia.

Chiung-Yuan Ko1, Wen-Ling Wang1, Chien-Feng Li1, Yung-Ming Jeng1, Yu-Yi Chu1, Han-Ying Wang1, Joseph T Tseng1, Ju-Ming Wang2.   

Abstract

Acute myeloid leukemia is the majority type presented in leukemia patients. Forcing malignant cells to undergo differentiation is 1 strategy for acute myeloid leukemia therapy. However, the failure of acute myeloid leukemia patients to achieve remission as a result of drug resistance remains a challenge. In this study, we found that the abundances of the proinflammatory cytokine IL-18 and its receptor (IL-18R) correlated with the occurrence of drug resistance in AML patients during standard treatment. Cyclooxygenase 2 (COX-2) has been suggested to have an antiapoptotic role in chemoresistant cancer cells. IL-18 treatment resulted in an increase in COX-2 expression through the post-transcriptional regulation of COX-2 mRNA in differentiated U937 cells and showed antiapoptotic activity in U937 and THP-1 cells. Two RNA-binding proteins, human antigen R and insulin-like growth factor mRNA-binding protein 3, mediated the stabilization of COX-2 mRNA. IL-18 induced the shuttling of human antigen R and insulin-like growth factor mRNA-binding protein 3 from the nucleus to the cytoplasm and facilitated their interaction; subsequently, this complex bound to the 3' untranslated region of COX-2 mRNA and affected its stability. We demonstrated further that JNK and/or ERK1/2 regulated human antigen R nucleocytoplasmic shuttling, mediating IL-18 stabilization of cyclooxygenase 2 mRNA. © Society for Leukocyte Biology.

Entities:  

Keywords:  differentiation therapy; drug resistance; post-transcriptional regulation

Mesh:

Substances:

Year:  2015        PMID: 26342105     DOI: 10.1189/jlb.2A0414-228RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  8 in total

1.  Expression Levels of Il-6 and Il-18 in Acute Myeloid Leukemia and Its Relation with Response to Therapy and Acute GvHD After Bone Marrow Transplantation.

Authors:  Mahdiyar Iravani Saadi; Mani Ramzi; Mehran Hosseinzadeh; Narjes Ebrahimi; Maryam Owjfard; Ehsan Nabi Abdolyousefi; Zahra Hesami; Behnaz Valibeigi; Neda Zareei; Fataneh Tavasolian; Hourvash Haghighinejad; Abdolhossein Zare
Journal:  Indian J Surg Oncol       Date:  2021-05-31

2.  miR-519 regulates the proliferation of breast cancer cells via targeting human antigen R.

Authors:  Lili Ren; Yong Li; Qun Zhao; Liqiao Fan; Bibo Tan; Aimin Zang; Hua Yang
Journal:  Oncol Lett       Date:  2019-12-20       Impact factor: 2.967

Review 3.  RNA methylation in hematological malignancies and its interactions with other epigenetic modifications.

Authors:  Lan Yao; Hua Yin; Mei Hong; Yajun Wang; Tingting Yu; Yao Teng; Tingting Li; Qiuling Wu
Journal:  Leukemia       Date:  2021-03-25       Impact factor: 12.883

4.  Downregulation of HuR Inhibits the Progression of Esophageal Cancer through Interleukin-18.

Authors:  Xiaohui Xu; Cheng Song; Zhihua Chen; Chenxiao Yu; Yi Wang; Yiting Tang; Judong Luo
Journal:  Cancer Res Treat       Date:  2017-02-24       Impact factor: 4.679

5.  4,5-Diaryl 3(2H)Furanones: Anti-Inflammatory Activity and Influence on Cancer Growth.

Authors:  Dmitrii Semenok; Jury Medvedev; Lefki-P Giassafaki; Iason Lavdas; Ioannis S Vizirianakis; Phaedra Eleftheriou; Antonis Gavalas; Anthi Petrou; Athina Geronikaki
Journal:  Molecules       Date:  2019-05-06       Impact factor: 4.411

Review 6.  IGF2BP3 From Physiology to Cancer: Novel Discoveries, Unsolved Issues, and Future Perspectives.

Authors:  Caterina Mancarella; Katia Scotlandi
Journal:  Front Cell Dev Biol       Date:  2020-01-15

Review 7.  The biological function of IGF2BPs and their role in tumorigenesis.

Authors:  Qiu-Ying Du; Zhi-Man Zhu; Dong-Sheng Pei
Journal:  Invest New Drugs       Date:  2021-07-12       Impact factor: 3.850

Review 8.  The Multifaceted Roles of Pyroptotic Cell Death Pathways in Cancer.

Authors:  Man Wang; Shuai Jiang; Yinfeng Zhang; Peifeng Li; Kun Wang
Journal:  Cancers (Basel)       Date:  2019-09-05       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.